Jeff Calcagno's Email Addresses & Phone Numbers

📖 Summary

Intern, Resident, Program Chief Resident, Clinical Psychopharmacology Fellow @ UCLA Neuropsychiatric Institute & Hospital U.C.L.A. is a top-three US psychiatry training program and one of the largest. Jeff became one of the program’s best residents while doing part-time strategy consulting (see below). Recognized for his leadership capabilities, he was selected as one of two Program Chief Residents and was awarded “Outstanding Resident of the Year” in Southern California. As Program Chief, he led 75+ residents responsible for covering wards and ERs of UCLA, West LA VA. After his residency, he was awarded a one-year clinical psychopharmacology research fellowship focusing on the care of treatment-resistant patients; he co-authored a paper in Journal of Clinical Psychiatry. From May 1993 to May 1998 (5 years 1 month) Greater Los Angeles AreaIndependent Management Consultant @ JLC Consulting Before and during residency, after a year of international travel, Jeff created and ran a small, independent healthcare research strategy and investment consultancy. Jeff conducted research and investment due diligence for venture funds and hedge funds. In work for Pfizer Health Solutions, he established a research basis for clinical algorithm software in one of the world’s first online disease management programs (in depression management). From June 1990 to April 1993 (2 years 11 months) International and Greater Los Angeles AreaPrincipal & Kauffman Fellow @ Scale Venture Partners Scale Venture Partners (ScaleVP) is a technology and healthcare fund managing over $1B in assets. Chosen as a Kauffman Fellow in a competitive matching process, Jeff completed a two-year venture education program while working full time at ScaleVP. He became proficient at deal sourcing, investment selection, and investment management. He served as active board observer and made investments in Ascenta Therapeutics (oncology), Horizon Therapeutics (pain), Orexigen Therapeutics (obesity), Prestwick Pharmaceuticals (HD), Sonexa Therapeutics (Alzheimer’s), and Zogenix (needle-free drug delivery). In addition, he authored articles in Venture Capital Journal and Nature Biotechnology and presented on national cable television. Website: http://www.scalevp.com/ From August 2006 to January 2011 (4 years 6 months) Foster City, CAJohnson & Johnson Innovation, JLABS - Head of JLABS San Francisco Bay Area @ Johnson & Johnson South San Francisco, CAJohnson & Johnson Innovation, CA - New Venture Transactions Lead & Global Transactions Lead @ Johnson & Johnson From January 2019 to May 2019 (5 months) South San Francisco, CAJohnson & Johnson Innovation, CA - New Venture Transactions Lead @ Johnson & Johnson From August 2014 to December 2018 (4 years 5 months) Menlo Park, CA, and South San Francisco, CAJohnson & Johnson Development Corporation, Principal @ Johnson & Johnson From January 2013 to July 2014 (1 year 7 months) Menlo Park, CAJohnson & Johnson Innovation CA - Senior Director, New Ventures @ Johnson & Johnson From August 2012 to December 2012 (5 months) Menlo Park, CASenior Director, Corporate Office of Science & Technology @ Johnson & Johnson From February 2011 to July 2012 (1 year 6 months) Fremont, CAChief Business Officer & Chief Financial Officer @ Vela Pharmaceuticals Vela was a 30-employee NJ-based startup pharma company funded by NEA and Venrock. Jeff was hired as CFO and quickly promoted to CFO & CBO. He was responsible for all aspects of Vela’s financial, operating, and business functions, including financials, budgeting, fund raising, partnerships, inlicensing, outlicensing, IP, legal, board and investor relations. Under his leadership Vela developed assets, for and ran clinical trials in, major depression and irritable bowel syndrome, achieving success through IND, Phase 1, and Phase 2a trials. Jeff built and led the transactions team, which negotiated in-licensing of a Phase 2 asset from Otsuka Pharmaceutical Group and he orchestrated a reverse-merger into a public company to access $45MM in cash. From July 2002 to August 2006 (4 years 2 months) Ewing, NJVP of Strategy & Corporate Development, Acting VP of Operations @ WIDCOMM, Inc. WIDCOMM, a 120-employee growth company, developed the world’s first Bluetooth software. Jeff led a strategic shift out of HCIT, making the company a horizontal enabler of chipsets and wireless devices. As the second-in-command business executive, he led many aspects of daily operations. Jeff was given the additional role of Acting VP of Operations in order to fix budget overruns and production delays, which he did. In addition, he was responsible for all capital raises. Jeff gave all investor presentations and orchestrated a $35MM Series B raise at 9X step-up to Series A. WIDCOMM withstood the telecom downturn and was acquired by Broadcom, which has shipped >1.5B products with WIDCOMM software. From September 1999 to May 2002 (2 years 9 months) San Diego, CAResearch Analyst; Associate to the Director of Research @ JP Morgan Hambrecht & Quist H&Q was a premier boutique investment bank focusing on innovative technology and healthcare growth companies; it was acquired by Chase in 1999, which was later acquired by J.P. Morgan. As a sell-side analyst, Jeff analyzed financial performance and authored investor reports for a portfolio of healthcare services companies. He scored in the top decile on the Series 7 exam. When H&Q cut back on its healthcare services franchise, Jeff was appointed to a newly created role supporting the research director across multiple initiatives. From June 1998 to August 1999 (1 year 3 months) San Francisco Bay AreaManagement Consultant @ McKinsey & Company McKinsey & Company is a premier global management consulting firm that serves leading businesses, governments, non-governmental organizations, and not-for-profits. One of McKinsey’s first physician-consultants, Jeff completed “Mini-MBA” training in finance and worked in McKinsey’s International Pharmaceutical & Life Sciences Practice. Jeff advised one of the world’s largest diversified healthcare company on multiple projects, including pharma asset portfolio prioritization and market introduction strategies. For a large, Swiss-based international pharma company he developed recommendations that cut drug development timelines by one year and reduced chronic R&D budget overruns. For another client, he identified potential pharma acquisition targets by analyzing clinical pipelines and creating risk-adjusted valuation models. From July 1988 to May 1990 (1 year 11 months) Greater New York City Area